CA-RESMED
ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit N30, the world’s first tube-down nasal cradle CPAP mask with a front-facing tube – a brand-new option for sleep apnea treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005138/en/
ResMed’s lightest mask yet, AirFit N30 features an adjustable elastic headgear, plus a nasal cradle cushion that sits under the nasal bridge, eliminating soreness in that area. The mask’s curved cushion is designed to provide a secure seal regardless of how the wearer sleeps or moves.
Together, these innovations help make starting and staying on CPAP therapy easier than ever for more of the 936 million people worldwide living with sleep apnea.
“AirFit N30 is about ease of use, helping people ease into therapy and addressing the most common pain points for longtime users,” said Jim Hollingshead, president of ResMed’s Sleep business. “As the first mask of its kind, AirFit N30 reflects ResMed’s continued leadership in sleep innovation – the cornerstone of our company for over 30 years.”
AirFit N30 joins ResMed’s award-winning portfolio of Minimalist CPAP masks designed to be small, light, and easy to use, including the popular AirFit P10 nasal pillows mask and AirFit F30 minimal-contact full-face mask.
AirFit N30 is now available in the United States, with other countries to follow.
About ResMed
At ResMed (NYSE: RMD) (ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191021005138/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease8.1.2026 13:00:00 CET | Press release
V-212 was well tolerated and demonstrated an excellent safety profileRobust IgG responses were observed to all three antigens in the vaccineResults support further development of V-212 independently and in combination with approved pneumococcal conjugate vaccines (PCVs) Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and immunogenicity in healthy volunteers, with data demonstrating an excellent safety profile and robust immune responses across all three target antigens in the vaccine. Results support further development of V-212 independently and in combination with an approved PCV. “With the significant need for an effective serotype-independent vaccine, we ar
Abbelight Announces Successful Series B Investment led by AVANT BIO to Accelerate Imaging Innovation and Scale Adoption Across a Broader Customer Base8.1.2026 12:36:00 CET | Press release
Abbelight, a global leader and a pioneer in super-resolution microscopy end-to-end solutions, today announced a successful Series B financing round led by AVANT BIO, a growth equity firm focused on enabling technologies shaping tomorrow’s therapeutics. “With a decade of experience in the Life Science Research market, Abbelight has been transforming the way scientists see, quantify, and interpret all kinds of complex intracellular mechanisms. It’s now time to tailor our cutting-edge imaging toolbox to also address new key verticals, such as single cell phenotyping and mechanisms of action validation for drug discovery”, says Nicolas Bourg CTO and co-founder. “Big things happen at the nanoscale - and Abbelight enables researchers to visualize precise sub-cellular structures like never before”, said Daniella Kranjac, Founding General Partner at AVANT BIO. “Their breakthroughs in super-resolution microscopy and sample-to-insight workflows embody the kind of enabling technologies that accel
FGS Global launches 2026 Radar Report: "A Rewired World"8.1.2026 11:00:00 CET | Press release
The post-war global order is fragmenting into spheres of influence as strongman leadership and transactional relationships replace multilateral cooperation, according to FGS Global's Radar 2026 report released today. FGS Global’s Radar is based on 175 in-depth interviews with senior global leaders and policy experts from the worlds of business, politics, academia and media and wide ranging, nationally representative polling of approximately 20,000 people across the US, Canada, the member countries of the European Union and Japan. We are in a Rewired World reshaped by the collapse of multilateral consensus and the rise of strongman leadership over weakened institutions. US-China competition is intensifying across trade, technology and space while traditional alliances fracture. At the same time, AI-driven disruption is accelerating change, populist disruptors are challenging established systems and influence is atomizing as mainstream media and political parties lose ground. The implica
GEOLOG Acquires Quad Ltd and QO Inc. to Enhance Global Wellsite Geology and Pore Pressure Services8.1.2026 11:00:00 CET | Press release
Strategic acquisition deepens GEOLOG’s technical expertise and broadens service delivery worldwide GEOLOG International B.V. (“GEOLOG” or the “Company”), a leading independent provider of wellsite geosciences, drilling solutions and surface logging services to the energy industry, today announced the successful acquisition of Quad Ltd and QO Inc. (together, “Quad”). Quad is a long-standing provider of wellsite and operations geologists, along with advanced pore pressure and fracture gradient analysis services. This strategic bolt-on acquisition significantly enhances GEOLOG’s portfolio of advanced subsurface and drilling support services and solidifies its operational presence globally. GEOLOG and Quad have a history of successful collaboration on numerous international projects, serving a broad spectrum of energy clients. Integrating Quad’s highly experienced personnel and specialized technical capabilities will strengthen GEOLOG’s capacity to support clients in complex drilling envir
Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 10:03:00 CET | Press release
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom